Literature DB >> 7741543

Assessing the preferences of patients with psoriasis. A quantitative, utility approach.

K A Zug1, B Littenberg, R D Baughman, T Kneeland, R F Nease, W Sumner, G T O'Connor, R Jones, E Morrison, R Cimis.   

Abstract

BACKGROUND AND
DESIGN: Patient preferences for health outcomes can be explicitly assessed and expressed in quantitative terms known as utilities. Three standard methods for utility assessment have been used to quantify patient preferences, but these methods have not previously been applied to skin disease. Eighty-seven patients with psoriasis from a tertiary medical center were interviewed, using an interactive, computer-based utility assessment questionnaire, U-Titer. Utilities for three categories of psoriasis severity and potential adverse outcomes of methotrexate therapy were assessed by the vertical rating scale, time trade-off, and standard gamble.
RESULTS: Patients assigned a broad range of utilities for each of the health states. Utilities obtained by the vertical rating scale did not correlate well with utilities obtained by standard gamble or time trade-off methods. However, utilities assessed by standard gamble and time trade-off were not significantly different. Patient characteristics such as age, gender, and education were not correlated with utility and did not explain the variation. Indicators of the patients' disease severity were not predictive of utilities for the assessed health states. The relatively high utility for liver biopsy suggests that there is less patient aversion to the procedure than suspected.
CONCLUSIONS: Utilities, or quantitative measures of patient preferences for health states, are measurable and vary widely for mild, moderate, and severe psoriasis and possible adverse outcomes of methotrexate treatment. The process of elucidating individual patient utilities for various health outcomes can be used to incorporate patient preferences into the process of clinical decision making. Guidelines that are based solely on severity of symptoms, without input from patients on how they value such symptoms, must be questioned.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7741543

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  17 in total

Review 1.  Valuing health-related quality of life. A review of health state valuation techniques.

Authors:  C Green; J Brazier; M Deverill
Journal:  Pharmacoeconomics       Date:  2000-02       Impact factor: 4.981

2.  The ethics of aggregation and hormone replacement therapy.

Authors:  A D Lyerly; E R Myers; R R Faden
Journal:  Health Care Anal       Date:  2001

3.  Validity of standard gamble utilities in patients referred for aortic valve replacement.

Authors:  Amjad I Hussain; Andrew M Garratt; Jan Otto Beitnes; Lars Gullestad; Kjell I Pettersen
Journal:  Qual Life Res       Date:  2015-11-24       Impact factor: 4.147

4.  Automated utility assessment of global health.

Authors:  R F Nease; R Tsai; L M Hynes; B Littenberg
Journal:  Qual Life Res       Date:  1996-02       Impact factor: 4.147

5.  Effect of locus of control and consideration of future consequences on time tradeoff utilities for current health.

Authors:  R M Handler; L M Hynes; R F Nease
Journal:  Qual Life Res       Date:  1997-01       Impact factor: 4.147

6.  Measuring women's preferences for breast cancer treatments and BRCA1/BRCA2 testing.

Authors:  M Cappelli; L Surh; L Humphreys; S Verma; D Logan; A Hunter; J Allanson
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

7.  Physicians' assessments of the utility of health states associated with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection.

Authors:  D K Owens; A B Cardinalli; R F Nease
Journal:  Qual Life Res       Date:  1997-01       Impact factor: 4.147

8.  Validity and responsiveness of the euroqol as a measure of health-related quality of life in people enrolled in an AIDS clinical trial.

Authors:  A W Wu; K L Jacobson; K D Frick; R Clark; D A Revicki; K A Freedberg; J Scott-Lennox; J Feinberg
Journal:  Qual Life Res       Date:  2002-05       Impact factor: 4.147

9.  Stability of time trade-off utilities for health states associated with the treatment of prostate cancer.

Authors:  Christopher S Saigal; Jeffrey Gornbein; Kristen Reid; Mark S Litwin
Journal:  Qual Life Res       Date:  2002-08       Impact factor: 4.147

Review 10.  A review of health utilities across conditions common in paediatric and adult populations.

Authors:  Jean-Eric Tarride; Natasha Burke; Matthias Bischof; Robert B Hopkins; Linda Goeree; Kaitryn Campbell; Feng Xie; Daria O'Reilly; Ron Goeree
Journal:  Health Qual Life Outcomes       Date:  2010-01-27       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.